Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (CLL). We report the preplanned subgroup analysis of 140 previously untreated, fit CLL patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosch, Francesc, Cantin, Guy, Cortelezzi, Agostino, Knauf, Wolfgang, Tiab, Mourad, Turgut, Mehmet, Zaritskey, Andrey, Merot, Jean-Louis, Tausch, Eugen, Trunzer, Kerstin, Robson, Susan, Gresko, Ekaterina, Böttcher, Sebastian, Foà, Robin, Stilgenbauer, Stephan, Leblond, Véronique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214269/
https://www.ncbi.nlm.nih.gov/pubmed/31455851
http://dx.doi.org/10.1038/s41375-019-0554-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214269/
https://www.ncbi.nlm.nih.gov/pubmed/31455851
http://dx.doi.org/10.1038/s41375-019-0554-1

Ejemplares similares